Aspira Women's Health Inc.

NasdaqCM:AWH Stock Report

Market Cap: US$11.7m

Aspira Women's Health Valuation

Is AWH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AWH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AWH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AWH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AWH?

Key metric: As AWH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AWH. This is calculated by dividing AWH's market cap by their current revenue.
What is AWH's PS Ratio?
PS Ratio1.3x
SalesUS$8.96m
Market CapUS$11.73m

Price to Sales Ratio vs Peers

How does AWH's PS Ratio compare to its peers?

The above table shows the PS ratio for AWH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.6x
SSKN STRATA Skin Sciences
0.4x8.0%US$12.9m
EKSO Ekso Bionics Holdings
0.9x23.8%US$15.5m
HLTH Cue Health
0.2x38.4%US$14.7m
SCND Scientific Industries
0.7xn/aUS$7.9m
AWH Aspira Women's Health
1.3x57.8%US$11.7m

Price-To-Sales vs Peers: AWH is expensive based on its Price-To-Sales Ratio (1.3x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does AWH's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$225.32m
ARAY Accuray
0.4x5.5%US$184.03m
NVRO Nevro
0.4x2.5%US$158.50m
KEQU Kewaunee Scientific
0.6xn/aUS$122.28m
AWH 1.3xIndustry Avg. 3.2xNo. of Companies50PS02.85.68.411.214+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AWH is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is AWH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AWH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: AWH is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AWH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.75
US$4.25
+468.3%
29.4%US$5.50US$3.00n/a2
Nov ’25US$0.90
US$4.25
+372.2%
29.4%US$5.50US$3.00n/a2
Oct ’25US$0.79
US$4.25
+439.3%
29.4%US$5.50US$3.00n/a2
Sep ’25US$1.03
US$4.25
+312.6%
29.4%US$5.50US$3.00n/a2
Aug ’25US$1.31
US$5.25
+300.8%
37.1%US$7.20US$3.30n/a2
Jul ’25US$0.99
US$5.25
+430.3%
37.1%US$7.20US$3.30n/a2
Jun ’25US$2.47
US$5.25
+112.6%
37.1%US$7.20US$3.30n/a2
Mar ’25US$4.00
US$5.60
+40.2%
28.6%US$7.20US$4.00n/a2
Feb ’25US$5.27
US$5.60
+6.3%
28.6%US$7.20US$4.00n/a2
Jan ’25US$4.08
US$4.80
+17.6%
16.7%US$5.60US$4.00n/a2
Dec ’24US$3.30
US$4.80
+45.5%
16.7%US$5.60US$4.00n/a2
Nov ’24US$4.69
US$4.80
+2.3%
16.7%US$5.60US$4.00US$0.902
Oct ’24US$5.36
US$4.80
-10.4%
16.7%US$5.60US$4.00US$0.792
Sep ’24US$6.00
US$4.80
-20.0%
16.7%US$5.60US$4.00US$1.032

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Elevance Health

US$92.2b

Operates as a health benefits company in the United States.

ELV

US$403.60

7D

-0.8%

1Y

-15.9%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

7D

2.8%

1Y

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

7D

-27.1%

1Y

80.4%